{"title":"Arthroscopic Treatment of Femoroacetabular Impingement Syndrome: An Updated Review.","authors":"Jung-Wee Park, Jung-Mo Hwang, Jeong Joon Yoo","doi":"10.4055/cios23307","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment strategies for femoroacetabular impingement (FAI) syndrome have evolved in tandem with increased comprehension of FAI's impact on hip joint health. Early intervention, including arthroscopic surgery, has gained popularity due to its potential to delay the progression of osteoarthritis. Arthroscopic surgery has demonstrated significant efficacy in treating FAI syndrome, with robust evidence from randomized controlled trials and systematic reviews supporting its use. Despite arthroscopic surgery's success, complications and reoperations are not uncommon. The incidence ranges from 1% to 31% and 4% to 13%, respectively. Adjunctive biologic treatments, such as bone marrow aspirate concentrates and platelet-rich plasma, have shown promise in chondral lesion management. However, robust evidence supporting their routine use in FAI syndrome is currently lacking. Among conservative treatment methods, intra-articular injections offer diagnostic and therapeutic benefits for FAI patients. While they may provide pain relief and aid in prognosis, their long-term efficacy remains a subject of debate. Comparative studies between conservative and arthroscopic treatments highlight the importance of personalized approaches in managing FAI syndrome. In conclusion, recent advancements in FAI syndrome management have illuminated various treatment modalities. Arthroscopic surgery stands as a pivotal intervention, offering substantial benefits in pain relief, function, and quality of life. However, careful patient selection and postoperative monitoring are crucial for optimizing outcomes. Adjunctive biologics and intra-articular injections show promise but require further investigation. Tailoring treatment to individual patient characteristics remains paramount in optimizing FAI syndrome management.</p>","PeriodicalId":47648,"journal":{"name":"Clinics in Orthopedic Surgery","volume":"16 4","pages":"517-525"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262938/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics in Orthopedic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4055/cios23307","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Treatment strategies for femoroacetabular impingement (FAI) syndrome have evolved in tandem with increased comprehension of FAI's impact on hip joint health. Early intervention, including arthroscopic surgery, has gained popularity due to its potential to delay the progression of osteoarthritis. Arthroscopic surgery has demonstrated significant efficacy in treating FAI syndrome, with robust evidence from randomized controlled trials and systematic reviews supporting its use. Despite arthroscopic surgery's success, complications and reoperations are not uncommon. The incidence ranges from 1% to 31% and 4% to 13%, respectively. Adjunctive biologic treatments, such as bone marrow aspirate concentrates and platelet-rich plasma, have shown promise in chondral lesion management. However, robust evidence supporting their routine use in FAI syndrome is currently lacking. Among conservative treatment methods, intra-articular injections offer diagnostic and therapeutic benefits for FAI patients. While they may provide pain relief and aid in prognosis, their long-term efficacy remains a subject of debate. Comparative studies between conservative and arthroscopic treatments highlight the importance of personalized approaches in managing FAI syndrome. In conclusion, recent advancements in FAI syndrome management have illuminated various treatment modalities. Arthroscopic surgery stands as a pivotal intervention, offering substantial benefits in pain relief, function, and quality of life. However, careful patient selection and postoperative monitoring are crucial for optimizing outcomes. Adjunctive biologics and intra-articular injections show promise but require further investigation. Tailoring treatment to individual patient characteristics remains paramount in optimizing FAI syndrome management.
随着人们对股骨髋臼撞击(FAI)综合征对髋关节健康影响的认识不断加深,股骨髋臼撞击综合征的治疗策略也在不断发展。由于早期干预(包括关节镜手术)具有延缓骨关节炎恶化的潜力,因此越来越受到人们的青睐。关节镜手术在治疗 FAI 综合征方面疗效显著,随机对照试验和系统综述的有力证据都支持其使用。尽管关节镜手术很成功,但并发症和再次手术并不少见。发生率分别为1%至31%和4%至13%。骨髓抽吸物浓缩物和富血小板血浆等辅助性生物治疗方法在软骨病变治疗中大有可为。然而,目前尚缺乏有力的证据支持将其常规用于FAI综合征。在保守治疗方法中,关节内注射可为 FAI 患者带来诊断和治疗上的益处。虽然注射可缓解疼痛并有助于预后,但其长期疗效仍存在争议。保守治疗与关节镜治疗之间的比较研究凸显了个性化方法在治疗 FAI 综合征中的重要性。总之,FAI 综合征治疗的最新进展阐明了各种治疗方法。关节镜手术是一种重要的干预手段,在缓解疼痛、改善功能和提高生活质量方面具有显著疗效。然而,谨慎选择患者和术后监测对于优化治疗效果至关重要。辅助性生物制剂和关节内注射显示出前景,但仍需进一步研究。在优化FAI综合征治疗的过程中,根据患者的个体特征进行治疗仍然至关重要。